FINWIRES · TerminalLIVE
FINWIRES

Update: Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%

By

(Updates with the stock movement in the headline and last paragraph.)

Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.

The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.

Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.

The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.

Telix Pharmaceuticals shares fell nearly 3% in recent Wednesday trade.

Related Articles

Asia

Update: Peter Warren Automotive Holdings' Wakeling Deal Faces ACCC Phase Two Competition Review; Shares Fall 3%

(Updates to add stock movement in the headline and last paragraph)Peter Warren Automotive Holdings' (ASX:PWR) planned purchase of 30 new car dealership sites from Wakeling Automotive Group will undergo a detailed phase two Australian Competition and Consumer Commission (ACCC) review after the competition regulator raised concerns about the deal's potential impact on market competition, according to an Australian bourse filing on Tuesday after market hours.The regulator did not approve the acquisition during its phase one assessment, saying that the merged company would own 25 of the region's 33 new car dealerships, per the filing. It is assessing how the deal could affect competition in new vehicle sales, as well as servicing and repair services.The ACCC has yet to make a final decision and is inviting public submissions until June 16, the filing added. The phase two review could take up to 90 business days.In a separate filing, Peter Warren Automotive said the companies will continue to work with the ACCC to address any concerns arising during the phase two review.The company's shares fell around 3% in recent Wednesday trade.

$ASX:PWR
Asia

Update: Cygnus Metals to Be Acquired by Central Asia Metals in AU$232 Million All-Scrip Deal; Shares Jump 27%

(Updates to add stock movement in the headline and the fifth paragraph)Cygnus Metals (ASX:CY5) agreed to be acquired by Central Asia Metals in an all-scrip deal that values each Cygnus share at AU$0.176, implying an equity value for the company of around AU$232 million, according to a late Tuesday filing with the Australian bourse.Under a definitive scheme implementation deed, Cygnus shareholders will receive 0.06 new Central Asia Metals share for each Cygnus share held.Existing Central Asia Metals shareholders will own about 70% of the company's enlarged fully diluted issued share capital after the deal, while Cygnus shareholders will own the remaining 30%.The transaction will give Central Asia Metals a flagship development-stage asset through a 100% interest in Canada's Chibougamau copper-gold project.The company's shares rose past 27% in recent trading on Wednesday.

$ASX:CY5
Asia

Biome Signs Binding Commercial Manufacturing Agreement for Activated Probiotics Products in Australia

Biome Australia (ASX:BIO) signed a binding commercial manufacturing agreement with Specialty Probiotics Australia, with an initial term of two years, as it seeks to transition manufacturing of its Activated Probiotics range to Australia, according to a Wednesday Australian bourse filing.The agreement requires no capital expenditure from Biome, and production in Australia will occur in smaller, more frequent batches. The first commercial batch is targeted for September, with the remaining range expected to move over around the following 18 months, subject to successful commercial scale-up and transition of production.Biome will supply the active ingredients, and Specialty Probiotics will carry out domestic manufacture and finishing.Biome will maintain its supply relationships with its European manufacturing partners to continue servicing European markets.

$ASX:BIO